Just two more days until the Total Body PET (TBPET) 2024 conference, the leading educational, scientific, research and networking event. The conference is expected to be attended by nuclear physicians, medical imaging specialists, (medical) physicists, scientists, clinicians, and industries with an interest in Total Body PET imaging. Meet us at the Forum in Groningen on 19-21 september: https://lnkd.in/eGaWfMeT
Advancing Nuclear Medicine
Geneesmiddelenproductie
Petten, Noord-Holland 2.093 volgers
Pioneering Medical Solutions
Over ons
Advancing Nuclear Medicine - Pioneering Medical Solutions Advancing Nuclear Medicine cares for the well-being of people worldwide. Especially for their health. We believe everybody should have access to advanced treatments. New highly targeted treatments will cause less side effects and improve the quality of life. We do our utmost to support the development of such medicaments and make them available around the world. Advancing Nuclear Medicine is an initiative of NRG and partners. NRG is the world leader in producing key ingredients for nuclear medicine. For the future we expect spectacular breakthroughs in the treatment of life threatening diseases by using targeted radiopharmaceuticals in a personalised approach. Our wish is to move forward, inspire and innovate the field of Nuclear Medicine, or, in short to be pioneering medical solutions. Let's connect! Follow us to: • Get inspired by new publications, blogs and articles about Nuclear Medicine every week • Connect with the right partners or academic institutions to move your idea forward • Get in contact with world leading experts in Nuclear Medicine • Find out more about our services & facilities to help you grow your own business • Benefit from years of study, research and experience in the field of Nuclear Medicine
- Website
-
http://www.advancingnuclearmedicine.com
Externe link voor Advancing Nuclear Medicine
- Branche
- Geneesmiddelenproductie
- Bedrijfsgrootte
- 501 - 1.000 medewerkers
- Hoofdkantoor
- Petten, Noord-Holland
- Specialismen
- Nuclear medicine, Healthcare, Nuclear technology, Research, R&D, Medicine, Biopharma, Pharmaceutical, Health, Isotopes, Translational Drug Development, Translational Drug Discovery en Radio pharmaceutical
Updates
-
Next week we will be attending the Total Body PET (TBPET) 2024 conference, the leading educational, scientific, research and networking event. The conference is expected to be attended by nuclear physicians, medical imaging specialists, (medical) physicists, scientists, clinicians, and industries with an interest in Total Body PET imaging. Visit our stand at the Forum in Groningen from 19-21 september. Let's meet! https://lnkd.in/eGaWfMeT
-
Do you want to receive our latest newsletter and stay up to date? Please go to our page: https://lnkd.in/gj85FESC
-
On Friday, 31 May, members of Control management of the Dutch Cancer Society visited NRG PALLAS at the Energy & Health Campus in Petten. NRG PALLAS provided an explanation of their contribution to the development of new nuclear medicines and the role of the new FIELD-LAB in this process. Read more: https://lnkd.in/eSGWMGXx
-
We are proud to announce that we installed our new Scientific Advisory Board (SAB) of NRG PALLAS at the Society of Nuclear Medicine and Molecular Imaging (SNMMI), last week in Toronto. Our SAB is chaired by Marnix Lam with members Erik Mittra, Niklaus Schaefer, Sandra Heskamp, Ghassan El-Haddad and Christophe Deroose. The SAB will provide expert guidance and advice on our projects within FIELD-LAB, and will ensure that our research, development, and strategic initiatives are grounded in robust scientific principles and methodologies. Key responsibilities include evaluating research proposals, advising on scientific trends and advancements. By offering an objective perspective, the SAB enhances the credibility and effectiveness of the organization's scientific endeavors, supporting innovation and informed decision-making. Overall, the SAB plays a crucial role in shaping the scientific direction and ensuring the integrity of the organisation's activities. #precisionmedicine #nuclearmedicine
-
On Friday, 31 May, the KWF Cancer Control management visited NRG PALLAS at the Energy & Health Campus in Petten. NRG PALLAS provided an explanation of their contribution to the development of new nuclear medicines and the role of the new FIELD-LAB in this process. Within FIELD-LAB, partners are collaborating on making medical isotopes available for clinical research to support new cancer treatments. From left to right: Patrick Ooms (KWF), Els Boter (KWF), Dorine Manson (KWF), Vinod Ramnandanlal (NRG PALLAS), Carla van Gils (KWF), Ronald Schram (NRG PALLAS), Karlijn van der Schilden (NRG PALLAS)
-
This week we will be attending the SNMMI Annual Meeting 2024 in Toronto. Want to meet up and talk about medical isotopes? https://lnkd.in/gUSrRHBz
-
NRGIPALLAS and Curium have signed a long-term agreement to expand the current cooperation to include the production of lutetium-177 (Lu-177). This will enable Curium to supply about 70,000 doses of Lu-177 annually, which will help about 14,000 patients per year. Read the full article: https://lnkd.in/grtbsyN6
-
On Wednesday, April 24th, the final discussion for one of the largest Kansen voor West II projects took place: FIELD-LAB. Representing Kansen voor West, Jeroen Elzenaar, Ruud van Raak en Tessa de Boer visited Petten to meet with Karlijn van der Schilden, Paula van der Vlies, Angelique de Boer-l'Istelle en Vinod Ramnandanlal. The Kansen voor West II project, named “Advancing Nuclear Medicine, Petten FIELD-LAB,” has resulted in a state-of-the-art GMP production facility. FIELD-LAB contributes to the acceleration of the development of new nuclear medicines. This facility is utilised for the production of promising radioactive materials for the preparation of innovative nuclear medications. FIELD-LAB also ensures the development of the necessary production processes. Significant achievements so far include a sustainable concept of a production system for two promising so-called starting materials and base material for two new therapies for cancer treatment. A tracer is being developed to better select patients for chemotherapy. Additionally, a dozen feasibility studies have been initiated for the product development of industrial parties. #precisionmedicine #healthcareinnovation #medicine #innovation
-
Last week, NRG|PALLAS (Yulia Buchatskaya and Fienke (J.A.M.) Nanne) attended the 21st European Symposium on Radiopharmacy & Radiopharmaceuticals (ESRR). The symposium showcased the current state of development of new Radiopharmaceuticals (nuclear medicine). We established many new connections and engaged in stimulating conversations. It is evident that this field of expertise is rapidly evolving and expanding. Consequently, there is growing interest and demand in products such as Pb-212 and Lu-177, both of which are under development at FIELD-LAB. #precisionmedicine #nuclearmedicine